ArticlePloS one2026
Development and internal validation of a risk stratification scoring system for identifying gram-negative ESBL-positive acute cholangitis: A retrospective cohort study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute cholangitis, a severe biliary infection that is frequently caused by gram-negative pathogens, presents health challenges owing to the increasing prevalence of antimicrobial resistance, particularly among extended-spectrum beta-lactamase (ESBL)-producing bacteria. Accurate risk stratification of patients with extended-spectrum beta-lactamase-producing bacteria is crucial for optimizing antimicrobial therapies.
aimsThis study aimed to develop and internally validate a risk stratification scoring system for identifying ESBL-producing bacteria in patients with acute cholangitis, with the goal of supporting clinical risk stratification.
methodsThis retrospective cohort analysis included adult patients with acute cholangitis admitted between 2019 and 2023. Patients were excluded if they had incomplete medical records, missing microbiological data, or non-adherence to the Tokyo Guidelines 2018 diagnostic criteria. Predictors of positivity for ESBL-producing bacteria were identified using multivariate logistic regression and integrated into a scoring system, and the performance metrics were evaluated.
resultsA total of 303 patients with positive blood or bile cultures were included in the analysis, of whom 111 (36.6%) had ESBL-positive cholangitis. Independent predictors of positivity for ESBL-producing bacteria included prior antibiotic treatment (3.5 points), chills with rigors (2.5 points), alanine aminotransferase levels <400 U/L (3.5 points), hematocrit levels <27% (2.5 points), and alkaline phosphatase levels >300 U/L (2.0 point). At cutoff scores of 7.5 and 11, the scoring system demonstrated sensitivity of 56% and 16%, specificity of 75% and 98%, positive predictive values of 56% and 82%, and overall accuracy of 68% and 70%, respectively.
conclusionsThis preliminary scoring system demonstrated high specificity at higher cutoffs, supporting its use as a rule-in tool for identifying patients at high risk of ESBL-producing bacteria in acute cholangitis. However, its moderate sensitivity limits its role as a rule-out strategy. This preliminary internally validated model should not be used to guide routine clinical decision-making without external multicenter validation, and any application must consider local resistance patterns and patient context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.